← 返回前沿论文

新型抗 Cadherin-17 单克隆抗体 Ca(17)Mab-5 的多方面应用

英文原题:A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca(17)Mab-5, for Multiple Applications.

查看英文原题

A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca(17)Mab-5, for Multiple Applications.

PubMed 2026/07/10(内容时间) Antibodies (Basel) Q3 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

Ca 17 Mab-5 是检测 CDH17 的多功能工具,具有肿瘤诊断的潜力。

研究思路结论见上方概要

Cadherin-17(CDH17,LI-cadherin)是一种非经典cadherin,具有非典型结构和独特功能。CDH17表达仅限于正常肠上皮。此外,CDH17作为一种癌蛋白,在结直肠癌、胃癌和胰腺癌中促进肿瘤迁移和侵袭。因此,CDH17是重要的诊断标志物和治疗靶点。针对CDH17的策略,包括单克隆抗体(mAbs)、双特异性抗体、抗体-药物偶联物(ADCs)和嵌合抗原受体(CAR)T细胞,已在临床前和临床研究中进行了评估。因此,开发能特异性识别细胞表面表达CDH17的mAbs对于推进肿瘤诊断和治疗至关重要。

抗人CDH17单克隆抗体(命名为Ca 17 Mabs)是通过用CDH17过表达细胞免疫小鼠并利用流式细胞术进行高通量筛选而开发的。

在Ca 17 Mabs中,一个克隆Ca 17 Mab-5(IgG 1,)通过流式细胞术特异性识别CDH17过表达的中国仓鼠卵巢-K1(CHO/CDH17)细胞,与另外21种CDH无可检测的交叉反应性。Ca 17 Mab-5还检测到人结直肠癌细胞系COLO201和COLO205中的内源性CDH17。Ca 17 Mab-5对CHO/CDH17和COLO205的表观解离常数(K D)值分别估计为1.5 10 -8 M和1.3 10 -8 M。此外,Ca 17 Mab-5通过Western blotting检测到内源性CDH17。在免疫组织化学中,Ca 17 Mab-5在正常结肠上皮、结直肠癌、胃癌和胰腺癌中表现出清晰的膜染色。

展开英文摘要原文

Anti-human CDH17 mAbs (named Ca 17 Mabs) were developed by immunizing a mouse with CDH17-overexpressed cells and a high-throughput screening using flow cytometry.

Among Ca 17 Mabs, a clone, Ca 17 Mab-5 (IgG 1 , ) specifically recognized CDH17-overexpressed Chinese hamster ovary-K1 (CHO/CDH17) cells with no detectable cross-reactivity to 21 other CDHs by flow cytometry. Ca 17 Mab-5 also detected endogenous CDH17 in human colorectal cancer cell lines, COLO201 and COLO205. The apparent dissociation constant ( K D ) values of Ca 17 Mab-5 for CHO/CDH17 and COLO205 were estimated as 1.5 10 -8 M and 1.3 10 -8 M, respectively. Furthermore, Ca 17 Mab-5 detected endogenous CDH17 by Western blotting. In immunohistochemistry, Ca 17 Mab-5 exhibited clear membranous staining in normal colon epithelium, colorectal, gastric, and pancreatic cancers.

Ca 17 Mab-5 is a versatile tool for detecting CDH17 and has potential for tumor diagnosis.

论文信息

作者
Ito R、Suzuki H、Ishikawa K、Yagi K、Ohkoshi A、Katori Y、Kaneko MK、Kato Y
单位
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.Japan
期刊
Antibodies (Basel, Switzerland)2026 Jul 10
原文标识
PubMed 42496285 · DOI 10.3390/antib15040059